Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Welcome to the TNL Beta! We are actively improving this experience.

Share Feedback

Source study found

Story checked

Compound YZG-331 leverages gut microbiota to improve sleep in mouse models of insomnia (opens in a new tab)

news-medical.net · 2026-11-05

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 1 supported
  • 5 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Notice: Analysis is currently derived from study abstracts. Full-text paper analysis capabilities are currently in development.

Share this check

Help improve NewsLink

Tell us what worked or what needs attention in this check.

Follow the evidence trail
1
2

NewsLink checks it

Mostly not supported

The one claim we could check holds up. One of six claims matches the study. This overall rating is based only on the claims we could check. Five claims the study doesn't address.

  • 1 supported
  • 5 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6Not coveredIn chemically induced and chronic restraint-induced insomnia mouse models, YZG-331 improved sleep-related measures and increased metabolites involved in the conversion of tryptophan to serotonin (5-HT).View evidenceHide evidence

Why this verdict

The profile supports the general points that YZG-331 improved insomnia-like/sedative-hypnotic outcomes in mice and regulated tryptophan metabolism/5-HT production. However, the abstract-level profile does not specify the exact insomnia models as chemically induced and chronic restraint-induced, nor does it give detailed sleep measures or metabolite panels. Those model-specific details cannot be verified from the supplied abstract-depth evidence.

1

Study evidence

YZG-331 produces sedative and hypnotic effects and ameliorates an insomnia-like phenotype in mice (asserted in abstract).

“YZG-331 exhibits significant sedative and hypnotic effects.”
2

Study evidence

YZG-331 enhanced activation of the tetrahydrobiopterin (BH4) cofactor system in mice.

“YZG-331 enhanced the activation of the tetrahydrobiopterin (BH4) cofactor system, which subsequently promoted tryptophan hydroxylase (TPH) activity, thereby enhancing 5-HT production.”
Claim 2 of 6Not coveredDepleting the gut microbiota substantially weakened YZG-331's effects, supporting a role for intestinal microbes.View evidenceHide evidence

As statedsubstantially

Why this verdict

The profile supports a general role for gut microbiota in YZG-331's mechanism, but it explicitly notes that the abstract does not describe the experimental manipulations used to demonstrate microbiota dependence. A claim that microbiota depletion substantially weakened YZG-331's effects, including the magnitude term 'substantially,' is therefore not verifiable at abstract depth.

1

Study evidence

YZG-331 produces sedative and hypnotic effects and ameliorates an insomnia-like phenotype in mice (asserted in abstract).

“YZG-331 exhibits significant sedative and hypnotic effects.”
Claim 3 of 6Not coveredThe article says Lactobacillus reuteri and its enzyme ribonucleoside hydrolase RihC contributed to conversion of YZG-331 into the metabolite M2, and that microbial hydroxylation of YZG-331 may support the BH4 cofactor system and tryptophan hydroxylase activity.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that Lactobacillus reuteri is implicated in YZG-331 metabolism and tryptophan-derived metabolite biosynthesis, and that YZG-331 activates the BH4-TPH-5-HT pathway. But the supplied profile does not mention the enzyme RihC, does not establish from abstract evidence that L. reuteri/RihC converts YZG-331 into M2, and does not mention microbial hydroxylation as the link to BH4. The hedging around hydroxylation helps, but the specific mechanistic details are not verifiable at this evidence depth.

1

Study evidence

YZG-331 increased the abundance of Lactobacillus and Muribaculaceae in the mouse gut.

“YZG-331 increased the abundance of Lactobacillus and Muribaculaceae in the gut”
2

Study evidence

YZG-331 enhanced activation of the tetrahydrobiopterin (BH4) cofactor system in mice.

“YZG-331 enhanced the activation of the tetrahydrobiopterin (BH4) cofactor system, which subsequently promoted tryptophan hydroxylase (TPH) activity, thereby enhancing 5-HT production.”
Claim 4 of 6Not coveredBoth YZG-331 and M2 increased intestinal butyric acid levels, were accompanied by changes in sleep-related signaling and improvements in intestinal barrier function, and YZG-331 also improved sleep measures in mice receiving gut microbiota from people with insomnia.View evidenceHide evidence

Why this verdict

The profile supports that YZG-331 and M2 increased intestinal butyric acid levels and links these changes to sleep regulation and intestinal barrier restoration. However, the claim also states that YZG-331 improved sleep measures in mice receiving gut microbiota from people with insomnia; that human-donor microbiota transfer detail is not present in the abstract-level profile. Because a material part of the claim is not available at this depth, the full claim is not verifiable from the supplied evidence.

1

Study evidence

YZG-331 produces sedative and hypnotic effects and ameliorates an insomnia-like phenotype in mice (asserted in abstract).

“YZG-331 exhibits significant sedative and hypnotic effects.”
2

Study evidence

YZG-331 and its metabolite M2 increased intestinal butyric acid levels; this change is reported to promote sleep regulation and to support restoration of the intestinal barrier.

“YZG-331 and M2 increased intestinal butyric acid levels, thereby promoting sleep regulation and supporting the restoration of the intestinal barrier.”
Claim 5 of 6Not coveredThe article notes limitations: the animal experiments used only female mice, the metabolic and microbial analyses involved small samples, and the proposed hydroxylation mechanism remains preliminary.View evidenceHide evidence

Why this verdict

The supplied abstract-depth profile does not verify most of these stated limitations as paper limitations. It reports female mice specifically for the oral bioavailability estimate, but not that all animal experiments used only female mice. It also says the abstract lacks sample sizes and mechanistic detail, but it does not itself verify that the metabolic and microbial analyses had small samples or that a proposed hydroxylation mechanism was described as preliminary. These caveats may come from full text or the article, but they are not verifiable from the abstract-level profile.

1

Study evidence

YZG-331 enhanced activation of the tetrahydrobiopterin (BH4) cofactor system in mice.

“YZG-331 enhanced the activation of the tetrahydrobiopterin (BH4) cofactor system, which subsequently promoted tryptophan hydroxylase (TPH) activity, thereby enhancing 5-HT production.”
2

Study evidence

Oral bioavailability of YZG-331 in female mice was quantified at 27.7%.27.7%

“the oral bioavailability of YZG-331 in female mice remains low at 27.7%”
Claim 6 of 6SupportedThe article says Acta Pharmaceutica Sinica B discusses how interactions between YZG-331 and the gut microbiota contribute to the compound's sleep-promoting effects in mouse models of insomnia.View evidenceHide evidence

Why this verdict

At abstract depth, the paper profile supports the broad headline claim that YZG-331's sleep/insomnia effects in mice are linked to gut microbiota interactions. The abstract-profile contributions state that YZG-331 ameliorates an insomnia-like phenotype via gut microbiota-dependent modulation of tryptophan metabolism/5-HT production, with microbiota also involved in YZG-331 metabolism and M2 formation. The headline wording is causal-sounding, but it tracks the paper's own abstract framing of a microbiota-dependent mechanism.

1

Study evidence

YZG-331 produces sedative and hypnotic effects and ameliorates an insomnia-like phenotype in mice (asserted in abstract).

“YZG-331 exhibits significant sedative and hypnotic effects.”
2

Study evidence

YZG-331 increased the abundance of Lactobacillus and Muribaculaceae in the mouse gut.

“YZG-331 increased the abundance of Lactobacillus and Muribaculaceae in the gut”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The abstract reports oral bioavailability of YZG-331 in female mice as 27.7%.

    This pharmacokinetic detail is in the paper profile but is not reflected in the story presentation, except indirectly through a caveat about female mice. The numerical bioavailability result is omitted.

    From in vivo pharmacokinetics and metabolite identification (female mice)

7 things the story did carry across
  • YZG-331 is reported to produce sedative/hypnotic effects and ameliorate an insomnia-like phenotype in mice through a gut microbiota-linked mechanism.
  • The paper links YZG-331 effects to modulation of tryptophan metabolism, BH4-TPH activation, and increased 5-HT production.
  • YZG-331 is reported to be unstable in the gut and rapidly metabolized, with M2 identified as a characteristic intestinal hydrolytic metabolite.
  • Gut microbiota changes include increased Lactobacillus and Muribaculaceae, with Lactobacillus reuteri singled out as playing a critical role in YZG-331 metabolism and tryptophan-derived metabolite biosynthesis.
  • YZG-331 and M2 increased intestinal butyric acid levels, which the authors link to sleep regulation and restoration of the intestinal barrier.
  • Female-mouse evidence is specifically stated for the oral bioavailability result, while sex-specificity and generalizability to other models or humans are not addressed in the abstract profile.
  • The abstract-profile evidence does not mention RihC or a microbial hydroxylation mechanism, despite supporting broader L. reuteri, M2, BH4-TPH, and 5-HT themes.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

5

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalYZG-331 ameliorates insomnia-like phenotype in mice via gut microbiota–dependent modulation of tryptophan metabolism/5-HT production, including BH4–TPH activation and downstream sleep regulation.in vivo mouse pharmacology (oral dosing)Expand

In plain English

In an in vivo mouse study, the compound YZG-331 is reported to produce sedative and hypnotic effects and to ameliorate an insomnia-like phenotype via interactions with the gut microbiota. The abstract states YZG-331 alters gut microbial composition (notably increasing Lactobacillus and Muribaculaceae, with Lactobacillus reuteri implicated), is rapidly metabolized in the gut to an intestinal hydrolytic metabolite M2, and modulates tryptophan metabolism and 5-HT production through activation of the BH4–TPH axis. YZG-331 and its metabolite M2 are also reported to increase intestinal butyric acid, which is linked to sleep regulation and intestinal barrier restoration. Oral bioavailability in female mice is reported as 27.7%.

Key findings

  • YZG-331 produces sedative and hypnotic effects and ameliorates an insomnia-like phenotype in mice (asserted in abstract).
  • The gut microbiota mediates modulation of tryptophan metabolism and 5-HT production by YZG-331, linked to activation of the BH4–TPH pathway.
“YZG-331 exhibits significant sedative and hypnotic effects.”
What this piece can’t prove
  • Abstract does not specify experimental design details (sample sizes, mouse strain/sex beyond bioavailability note, dosing regimen, controls, or exact sleep assays).

2 further details could not be confirmed from the summary.

2in vivo animalYZG-331 ameliorates insomnia-like phenotype in mice via gut microbiota–dependent modulation of tryptophan metabolism/5-HT production, including BH4–TPH activation and downstream sleep regulation.in vivo animal microbiome profilingExpand

In plain English

In mice, oral YZG-331 was reported to alter gut microbiota composition — increasing the abundance of Lactobacillus and Muribaculaceae — and Lactobacillus reuteri was singled out as playing a critical role in both YZG-331 metabolism and the biosynthesis of tryptophan-derived metabolites, linking these taxonomic shifts to modulation of tryptophan/5‑HT pathways.

Key findings

  • YZG-331 increased the abundance of Lactobacillus and Muribaculaceae in the mouse gut.
  • Lactobacillus reuteri was reported to play a critical role in YZG-331 metabolic processing and in the biosynthesis of tryptophan-derived metabolites.
“YZG-331 increased the abundance of Lactobacillus and Muribaculaceae in the gut”
What this piece can’t prove

3 further details could not be confirmed from the summary.

3in vivo animalYZG-331 ameliorates insomnia-like phenotype in mice via gut microbiota–dependent modulation of tryptophan metabolism/5-HT production, including BH4–TPH activation and downstream sleep regulation.in vivo animal mechanistic assays (BH4/TPH/5-HT)Expand

In plain English

Abstract reports that in YZG-331–treated mice the tetrahydrobiopterin (BH4) cofactor system was activated, which promoted tryptophan hydroxylase (TPH) activity and thereby increased 5-hydroxytryptamine (5-HT) production; these host-pathway changes are presented as part of the mechanism linking YZG-331 action to modulation of tryptophan metabolism/5-HT and sleep regulation.

Key findings

  • YZG-331 enhanced activation of the tetrahydrobiopterin (BH4) cofactor system in mice.
  • BH4 activation was reported to promote tryptophan hydroxylase (TPH) activity.
“YZG-331 enhanced the activation of the tetrahydrobiopterin (BH4) cofactor system, which subsequently promoted tryptophan hydroxylase (TPH) activity, thereby enhancing 5-HT production.”
What this piece can’t prove

2 further details could not be confirmed from the summary.

4in vivo animalGut microbiota mediates YZG-331 intestinal metabolism (instability/rapid metabolism) with hydrolytic metabolite M2 as a characteristic metabolite; specific taxa (notably Lactobacillus reuteri) are implicated in the metabolic processing of YZG-331 and in producing tryptophan-derived metabolites.in vivo pharmacokinetics and metabolite identification (female mice)Expand

In plain English

The abstract reports that oral bioavailability of YZG-331 in female mice is low (27.7%) and that the compound is unstable in the gut, undergoing rapid microbiota-associated metabolism with an intestinal hydrolytic metabolite (M2) identified as a characteristic metabolite. Changes in gut bacterial taxa (increased Lactobacillus and Muribaculaceae) are reported, and Lactobacillus reuteri is specifically implicated in both metabolic processing of YZG-331 and production of tryptophan-derived metabolites.

Key findings

  • Oral bioavailability of YZG-331 in female mice was quantified at 27.7%.27.7%
  • YZG-331 shows instability in the gut and undergoes rapid metabolism; an intestinal hydrolytic metabolite (M2) was identified as a characteristic metabolite.
“the oral bioavailability of YZG-331 in female mice remains low at 27.7%”
What this piece can’t prove
  • The abstract does not specify the assays or evidence used to link gut microbiota (and specific taxa) causally to YZG-331 metabolism.

3 further details could not be confirmed from the summary.

5in vivo animalYZG-331 and its metabolite M2 increase intestinal butyric acid levels, supporting sleep regulation and restoration of the intestinal barrier.in vivo animalExpand

In plain English

The abstract reports that oral YZG-331 and its intestinal hydrolytic metabolite M2 increased intestinal butyric acid (butyrate) levels in an in vivo animal setting, and that these changes are linked to promotion of sleep regulation and support for restoration of the intestinal barrier.

Key findings

  • YZG-331 and its metabolite M2 increased intestinal butyric acid levels; this change is reported to promote sleep regulation and to support restoration of the intestinal barrier.
“YZG-331 and M2 increased intestinal butyric acid levels, thereby promoting sleep regulation and supporting the restoration of the intestinal barrier.”
What this piece can’t prove
  • No effect magnitudes, confidence intervals, or statistical significance values are provided for butyrate, sleep, or barrier outcomes.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 28 candidate papers

Candidate

Author correction to “Human carboxylesterases: a comprehensive review” [Acta Pharmaceutica Sinica B 8 (2018) 699-712]

Acta Pharmaceutica Sinica B · 2026 · Crossref

Source (opens in a new tab)

And 22 more candidates considered.